Neuromyelitis Optica Treatments
Find Neuromyelitis Optica Treatments
Medications for Neuromyelitis Optica
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Neuromyelitis Optica.
Found 4 Approved Drugs for Neuromyelitis Optica
Eculizumab
Brand Names
Soliris, BKEMV, Epysqli
Eculizumab
Brand Names
Soliris, BKEMV, Epysqli
Form: Injection
Method of administration: Intravenous
FDA approval date: April 02, 2007
Classification: Complement Inhibitor
EPYSQLI is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Uplizna
Generic Name
Inebilizumab
Uplizna
Generic Name
Inebilizumab
Form: Injection
Method of administration: Intravenous
FDA approval date: June 11, 2020
Classification: CD19-directed Cytolytic Antibody
UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. UPLIZNA is a CD19-directed cytolytic antibody indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1 )
Enspryng
Generic Name
Satralizumab
Enspryng
Generic Name
Satralizumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: August 14, 2020
ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1 )
Ultomiris
Generic Name
Ravulizumab
Ultomiris
Generic Name
Ravulizumab
Form: Solution
Method of administration: Intravenous
FDA approval date: December 21, 2018
Classification: Complement Inhibitor
ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances